SCHEDULE: T. Rowe Price Cuts INSMED Stake Below 5%

T. Rowe Price Associates, Inc. has reduced its beneficial ownership in INSMED INC to 3.3% as reported in its latest Schedule 13G amendment.

Summary

• T. Rowe Price Associates, Inc. filed an Amendment No. 15 to Schedule 13G for INSMED INC.
• The filing reports T. Rowe Price's beneficial ownership of INSMED INC common stock as 6,932,009 shares, representing 3.3% of the class.
• This indicates a reduction in ownership from a previous stake that would have been above 5%, triggering the initial Schedule 13G filing.
• T. Rowe Price Associates, Inc. holds sole voting power over 6,811,698 shares and sole dispositive power over 6,931,466 shares.
• The event requiring the filing of this statement occurred on September 30, 2025.

Sentiment

Score: 4

Explanation: The reduction in a significant institutional investor's stake from above 5% to 3.3% is generally perceived as a negative signal, indicating a potential loss of confidence or reallocation of capital, hence a slightly negative sentiment.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may view the reduction in T. Rowe Price's stake as a negative signal, potentially leading to decreased investor confidence or downward pressure on the stock price.

Key Dates

Recommendation

T. Rowe Price Associates, Inc. has reduced its beneficial ownership in INSMED INC to 3.3%, down from a previous stake that would have been above 5%. This reduction by a significant institutional investor could signal a re-evaluation of the company's prospects or a reallocation of capital, warranting a cautious 'hold' recommendation for existing shareholders and further due diligence for potential investors.

Keywords

INSMED INC, T. Rowe Price Associates, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Equity Stake